PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes

Liver International

Volumn 31, Issue 9, 2011, Pages 1332-1336

  Petit, Jean M ^a,b   Guiu, Boris ^a,b   Masson, David ^a   Duvillard, Laurence ^a   Jooste, Valerie ^a   Buffier, Perrine ^b   Bouillet, Benjamin ^a,b   Brindisi, Marie Claude ^a,b   Robin, Isabelle ^b   Gambert, Philippe ^a   Verges, Bruno ^a,b   Cercueil, Jean Pierre ^b   Hillon, Patrick ^a,b  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b HÔPITAL DU BOCAGE   (France)

Author keywords

1H spectroscopy; Adiponutrin; FibroTest; Liver fibrosis; Non alcoholic fatty liver disease; Steatosis; Type 2 diabetes

Indexed keywords

ADULT; ALLELE; ARTICLE; BODY MASS; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENE; HOMOZYGOSITY; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PNPLA3 GENE; PROTON NUCLEAR MAGNETIC RESONANCE; STEATOSIS;

AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; FRANCE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HOMOZYGOTE; HUMANS; LIPASE; LIVER; LIVER CIRRHOSIS; LOGISTIC MODELS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MEMBRANE PROTEINS; MIDDLE AGED; ODDS RATIO; PHENOTYPE; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 80052548880     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02566.x     Document Type: Article

References (24)

1. Cusi K. Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2009; 16: 141-9.
2. Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30: 1212-8.
3. Petit JM, Guiu B, Terriat B, et al. Non-alcoholic fatty liver is not associated with carotid intima-media thickness in type 2 diabetic patients. J Clin Endocrinol Metab 2009; 94: 4103-6.
4. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461-5.
5. Kantartzis K, Peter A, Machicao F, et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 2009; 58: 2616-23.
6. Kotronen A, Johansson LE, Johansson LM, et al. common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 2009; 52: 1056-60.
7. Sookoian S, Castaño GO, Burgueño AL, et al. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res 2009; 50: 2111-6.
8. He S, McPhaul C, Li JZ, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 2010; 285: 6706-15.
9. Valenti L, Al-Serri A, Daly AK, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51: 1209-17.
10. Rotman Y, Koh C, Zmuda JM, et al. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010; 52: 894-903.
11. Speliotes EK, Butler JL, Palmer CD, et al. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 2010; 52: 904-12.
12. Petit JM, Guiu B, Masson D, et al. Specifically-PNPLA3-mediated accumulation of liver fat in obese patients with type 2 diabetes. J Clin Endocrinol Metab 2010; 95: E430-6.
13. Kotronen A, Juurinen L, Hakkarainen A, et al. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care 2008; 31: 165-9.
14. Guiu B, Petit JM, Loffroy R, et al. Quantification of liver fat content: comparison of triple-echo chemical shift gradient-echo imaging and in vivo proton MR spectroscopy. Radiology 2009; 250: 95-102.
15. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-95.
16. Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005; 288: E462-8.
17. Ratziu V, Massard J, Charlotte F, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 14: 6-6.
18. Poynard T, Morra R, Halfon P, et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007; 15: 40.
19. Imbert-Bismut F, Messous D, Thibault V, et al. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med 2004; 42: 323-3.
20. Adams LA, Harmsen S, St Sauver JL, et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol 2010; 105: 1567-73.
21. de Marco R, Locatelli F, Zoppini G, et al. Cause-specific mortality in type 2 diabetes The Verona Diabetes Study. Diabetes Care 1999; 22: 756-61.
22. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-62.
23. Halfon P, Munteanu M, Poynard T. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol Clin Biol 2008; 32: 22-39.
24. Jacqueminet S, Lebray P, Morra R, et al. Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes. Clin Gastroenterol Hepatol 2008; 6: 828-31.